Last reviewed · How we verify

GSK573719/VI 62.5/25 — Competitive Intelligence Brief

GSK573719/VI 62.5/25 (GSK573719/VI 62.5/25) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GSK573719/VI 62.5/25 (GSK573719/VI 62.5/25) — GlaxoSmithKline. GSK573719/VI 62.5/25 is a combination of umeclidinium (long-acting muscarinic antagonist) and vilanterol (long-acting beta-2 agonist) that relaxes airway smooth muscle to improve airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK573719/VI 62.5/25 TARGET GSK573719/VI 62.5/25 GlaxoSmithKline phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
Tiotropium & olodaterol Tiotropium & olodaterol University of Dundee marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
UMEC/VI UMEC/VI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
GSK 573719 +GW642444 125/25 GSK 573719 +GW642444 125/25 GlaxoSmithKline phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; Beta-2 adrenergic receptor
Glycopyrronium/Formoterol Fumarate Glycopyrronium/Formoterol Fumarate AstraZeneca phase 3 LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) Muscarinic M3 receptor; Beta-2 adrenergic receptor
Umeclidinium / Vilanterol Dry Powder Inhaler Umeclidinium / Vilanterol Dry Powder Inhaler Gary L. Pierce marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
UMEC/VI DPI UMEC/VI DPI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class)

  1. GlaxoSmithKline · 5 drugs in this class
  2. University of Dundee · 2 drugs in this class
  3. National Institute of Respiratory Diseases, Mexico · 1 drug in this class
  4. University of Tennessee Graduate School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK573719/VI 62.5/25 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk573719-vi-62-5-25. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: